Reinventing the renin-angiotensin-aldosterone system based on experience from the COVID-19 pandemic

被引：0
作者：
Kurbel, Sven [1 ]
机构：
[1] Josip Juraj Strossmayer Univ Osijek, Med Fac, Osijek, Croatia
来源：
JOURNAL OF PHYSIOLOGY-LONDON | 2024年 / 602卷 / 20期
关键词：
ACE; ACE2; COVID-19; RAAS;
D O I：
10.1113/JP287202
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
[No abstract available]
引用
收藏
页码：5119 / 5124
页数：6
相关论文
共 50 条
  • [21] Renin-Angiotensin-Aldosterone System Inhibitors and the Risk of AKI in COVID-19 Compared with Influenza
    Birkelo, Bethany C.
    Parr, Sharidan K.
    Perkins, Amy M.
    Greevy Jr, Robert A. A.
    Arroyo, Juan Pablo
    Hung, Adriana M.
    Vincz, Andrew J.
    Shah, Shailja C.
    Kapoor, Tarun
    Matheny, Michael E.
    Siew, Edward D.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 17 (03): : 423 - 425
  • [22] Fallacies in medical practice: Renin-angiotensin-aldosterone system inhibition and COVID-19 as a Paradigm
    Triposkiadis, Filippos
    Boudoulas, Konstantinos Dean
    Xanthopoulos, Andrew
    Boudoulas, Harisios
    HELLENIC JOURNAL OF CARDIOLOGY, 2021, 62 (03) : 185 - 189
  • [23] Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection or Hospitalization: A Cohort Study
    Dublin, Sascha
    Walker, Rod L.
    Floyd, James S.
    Shortreed, Susan M.
    Fuller, Sharon
    Albertson-Junkans, Ladia
    Harrington, Laura B.
    Greenwood-Hickman, Mikael Anne
    Green, Beverly B.
    Psaty, Bruce M.
    AMERICAN JOURNAL OF HYPERTENSION, 2021, 34 (04) : 339 - 347
  • [24] COVID-19 and renin angiotensin aldosterone system: Pathogenesis and therapy
    Babajani, Fatemeh
    Kakavand, Atefeh
    Mohammadi, Hossien
    Sharifi, Armin
    Zakeri, Saba
    Asadi, Soheila
    Afshar, Zeinab Mohseni
    Rahimi, Zohreh
    Sayad, Babak
    HEALTH SCIENCE REPORTS, 2021, 4 (04)
  • [25] Activation of the renin-angiotensin-aldosterone system is associated with Acute Kidney Injury in COVID-19
    Dudoignon, Emmanuel
    Moreno, Nabila
    Deniau, Benjamin
    Coutrot, Maxime
    Longer, Romain
    Amiot, Quentin
    Mebazaa, Alexandre
    Pirracchio, Romain
    Depret, Francois
    Legrand, Matthieu
    ANAESTHESIA CRITICAL CARE & PAIN MEDICINE, 2020, 39 (04) : 453 - 455
  • [26] Renin-Angiotensin-Aldosterone System Blockers Prior to Hospitalization and Their Association With Clinical Outcomes in Coronavirus Disease 2019 (COVID-19)
    Banwait, Ranjit
    Singh, Devina
    Blanco, Anamarys
    Rastogi, Vaibhav
    Abusaada, Khalid
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (02)
  • [27] Renin-angiotensin-aldosterone system blockers in Bulgarian COVID-19 patients with or without chronic kidney disease
    Filev, Rumen
    Rostaing, Lionel
    Lyubomirova, Mila
    Bogov, Boris
    Kalinov, Krassimir
    Svinarov, Dobrin
    MEDICINE, 2022, 101 (48) : E31988
  • [28] Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors
    Golpe, Rafael
    Perez-de-Llano, Luis A.
    Dacal, David
    Guerrero-Sande, Hector
    Pombo-Vide, Beatriz
    Ventura-Valcarcel, Pablo
    MEDICINA CLINICA, 2020, 155 (11): : 488 - 490
  • [29] Should we continue to use renin-angiotensin-aldosterone system blockers in patients with COVID-19?
    Copur, Sidar
    Kanbay, Asiye
    Kanbay, Mehmet
    CLINICAL KIDNEY JOURNAL, 2022, 15 (05) : 852 - 854
  • [30] Is Spironolactone the Preferred Renin-Angiotensin-Aldosterone Inhibitor for Protection Against COVID-19?
    Wilcox, Christopher S.
    Pitt, Bertram
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 77 (03) : 323 - 331
12345